(PRWEB) June 17, 2013
Takeda Pharmaceutical Company Limited (Takeda) and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that NESINA (alogliptin) and the fixed-dose combination therapies KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone) are now available by prescription in pharmacies in the United States (U.S.). These medications are approved by the U.S. Food and Drug Administration (FDA) for the treatment of type 2 diabetes in adults, as adjuncts to diet and exercise.
“Diabetes is an increasingly complex disease, and many patients require treatment to be individualized to their needs,” said Jennifer Greeby, senior director, diabetes and obesity marketing, Takeda Pharmaceuticals U.S.A., Inc. “The availability of NESINA, KAZANO and OSENI marks an important milestone in Takeda's commitment to patients living with type 2 diabetes, and provides new options for physicians.”
NESINA is a dipeptidyl peptidase-4 inhibitor (DPP-4i) that is designed to slow the inactivation of incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide). KAZANO combines alogliptin with metformin HCl, a widely used anti-diabetes medication, in a single tablet. OSENI combines alogliptin with the thiazolidinedione (TZD) pioglitazone, and is the first product in the U.S. to include both a DPP-4i and TZD in a single tablet.
Takeda has conducted extensive clinical research around NESINA, including placebo- and active-controlled clinical trials involving more than 13,000 patients, and is committed to the ongoing study of NESINA and the fixed-dose combinations KAZANO and OSENI. This month, Takeda will present new data surrounding these therapies at the upcoming American Diabetes Association (ADA) Scientific Sessions, June 21-25 in Chicago, IL.
Takeda’s fiscal 2013 financial outlook announced on May 9, 2013 includes the launches
Copyright©2012 Vocus, Inc.
All rights reserved